Studies on Viral Epitopes on Vaccine Particles to Inform Vaccine Development
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 15 February 2025 | Viewed by 94
Special Issue Editor
Special Issue Information
Dear Colleagues,
Researchers have made a remarkable advancement in the development of vaccine particles, such as nanoparticles (NPs) and virus-like particles (VLPs). NPs may consist of self-assembled protein NPs, liposome-based NPs, bacterial phage virus-like particles, lipid nanoparticles (LNPs), and micelles. VLPs can be enveloped or non-enveloped, structurally and antigenically mimic natural viruses, but do not contain viral genetic materials. These vaccine particles serve as antigen or antigenic epitope carriers and vaccine adjuvants. The multiple copies of antigens or antigenic epitopes presented on the surfaces of NPs or VLPs promote cross-linking of B cell receptors and significantly improve immunogenicity. LNPs that encapsulate nucleic acids, which produce antigens in vivo, have exhibited a profound promise for developing particle-based vaccines against infectious diseases and cancers. Although vaccine particle technology offers immense advantages, many critical challenges still exist in successfully developing a vaccine particle-based vaccine for clinical application.
This Special Issue aims to address recent scientific progress and methodologies, as well as preclinical or clinical studies relevant to vaccine research and development. We welcome original research articles, original reports, original observations, and in-depth reviews.
Dr. Yongping Yang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine particle
- nanoparticle (NP)
- virus-like particle (VLP)
- self-assembly
- liposome
- lipid nanoparticle (LNP)
- polymeric micelle
- polymer
- preventive vaccine
- cancer vaccine
